Latest News - Biogen
Top Corporates Hub
Biogen
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts
26.05.2026 00:06
Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
19.05.2026 10:30
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" W. Bonney, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective May 16, 2026. Simona Skerjanec, M.Pharm, MBA, will transition from Interim Chairperson to continue serving as a member of the Board.
How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus
19.05.2026 04:34
Alector’s updated analyst framework now points to a fair value move from US$2.88 to US$3.10, a modest shift that still signals a meaningful recalibration of expectations. This change is closely tied to how analysts are weighing CELIA’s readthrough for tau-targeting therapies and Alector’s pivot toward blood brain barrier shuttle based designs, balancing the scientific promise against execution risks and the memory of prior trial setbacks. As you read on, you will see how to track these moving...
BIIB SHAREHOLDER INVESTIGATION: SueWallSt Investigates Biogen Inc. for Possible Securities Law Violations
18.05.2026 09:03
Biogen Phase 2 CELIA trial data sent shares down 6.4% after it was revealed that topline data missed its primary endpoint.NEW YORK, May 18, 2026 /PRNewswire/ -- Biogen Inc. shareholders lost 6.4% per...
Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls
15.05.2026 13:45
Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls
Biogen completes $5.3B Apellis Pharmaceuticals acquisition
15.05.2026 11:44
Apellis, maker of eye disease drug SYFOVRE and kidney drug EMPAVELI, is now a wholly owned Biogen subsidiary
Biogen: Apellis Acquisition, Alzheimer's Fail Sums Up Mixed Investment Opportunity
15.05.2026 11:10
Biogen Inc. upgraded to Hold: Apellis deal adds revenue, MS stable but pipeline delays persist. Click for this updated look at BIIB following Q1 earnings.
The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer's Pathologies in Biogen's Phase 2 Tau Study
15.05.2026 00:48
Today, Biogen announced topline results from the Phase 2 CELIA study of diranersen, an investigational therapy designed to target tau in people with early Alzheimer's disease. While the study did not meet its primary endpoint, Biogen reported reductions in tau and signals of slowed cognitive decline and plans to advance the drug into further trials.
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
14.05.2026 11:05
CARLSBAD, Calif., May 14, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from the Phase 2 CELIA study evaluating diranersen (IONIS-MAPTRx/BIIB080), an investigational antisense oligonucleotide (ASO) therapy targeting tau, in individuals with early Alzheimer’s disease (AD). The CELIA results provide the first evidence from a randomized Phase 2 study of a tau-directed therapy demonstrating both robust biomarker impact an
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
14.05.2026 10:59
CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational developmentRobust reductions in tau pathology were observed across all studied doses, with results generally consistent with those observed in the Phase 1b study1Pre-specified analyses of cognitive endpoints demonstrated slowing of clinical decline across all studied doses, particularly at the lowest doseThe safety and tol
Biogen to advance experimental Alzheimer's drug despite mid-stage trial miss
14.05.2026 08:08
Biogen said on Thursday itwas advancing its experimental Alzheimer’s drug to late-stagetrials despite the treatment failing to meet the main goal of amid-stage study. Shares of the...
Topline results from phase 2 Celia study of diranersen, first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease
14.05.2026 07:45
Biogen Inc: Topline results from phase 2 Celia study of diranersen : first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's disease Biogen -...
3 Healthcare Stocks We’re Skeptical Of
14.05.2026 04:52
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently - over the past six months, the collective 3.7% gain for healthcare stocks has fallen short of the S&P 500’s 7.1% rise.
Biogen Inc. (BIIB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
13.05.2026 17:10
Biogen Inc. (BIIB) Bank of America Global Healthcare Conference 2026 May 13, 2026 2:20 PM EDTCompany ParticipantsAdam MeyersConference Call...
Transcript : Biogen Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 11
13.05.2026 15:35
Presenter SpeechJason Zemansky Annual Healthcare Conference in Tasty Las Vegas. My name is Jason Zemansky. I'm one of the mid-cap analysts here at the bank. Very pleased to have join me Biogen and...
3 Value Stocks We Approach with Caution
12.05.2026 10:28
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Is Biogen Inc. (BIIB) one of the Best Biotech Stocks to Invest In According to Billionaire Steve Cohen?
12.05.2026 00:05
Biogen Inc. (NASDAQ:BIIB) is the Best Biotech Stock. On April 20, 2026, Reuters reported that Biogen Inc. (NASDAQ:BIIB) had agreed to pay up to $850 million for the exclusive Greater China rights to felzartamab. It is an experimental immune therapy developed by Chinese biotech TJ Biopharma, bringing the drug’s global commercial coverage to a close. TJ […]
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
08.05.2026 06:30
TOKYO and CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once-weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIK™) as a starting dose for the treatment of early Alzheimer’s disease. The new Prescription Drug User Fee Act (PDUFA) action date is Au
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
08.05.2026 06:30
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once‑weekly lecanemab‑irmb subcutaneous injection (U.S. brand name: LEQEMBI® IQLIK™) as a starting dose for the treatment of early Alzheimer's disease. The new Prescription Drug User Fee Act (PDUFA) action date is August 24, 2026.